More issues

How to Get Kymriah (tisagenlecleucel) Covered by UnitedHealthcare in Virginia: Complete Prior Authorization and Appeals Guide

Answer Box: Getting Kymriah Covered by UnitedHealthcare in Virginia UnitedHealthcare covers Kymriah (tisagenlecleucel) under medical benefits as autologous stem cell therapy, requiring prior authorization through OptumHealth Transplant Solutions. For B-cell ALL (≤25 years) or relapsed/refractory DLBCL after ≥2 therapy lines, submit via the UHC Provider Portal with CD19+ confirmation,
6 min read

Work With Your Doctor to Get Acthar Gel Covered by Cigna in North Carolina: Complete Prior Authorization and Appeals Guide

Answer Box Getting Acthar Gel (repository corticotropin injection) covered by Cigna in North Carolina requires prior authorization approval before dispensing through Express Scripts' Accredo specialty pharmacy. Your fastest path: (1) Verify your diagnosis meets Cigna's approved conditions (infantile spasms, MS exacerbations, rheumatologic disorders), (2) Document corticosteroid failure/
7 min read

How to Get Xembify (Immune Globulin SC) Covered by Florida Blue Cross Blue Shield: Prior Authorization, Appeals, and Alternative Options Guide

Quick Answer: Xembify (immune globulin SC) requires prior authorization from Florida Blue Cross Blue Shield for primary immunodeficiency. Submit PA 60-75 days before needed with diagnosis labs (low IgG), infection history, and failed IVIG/SCIG trials. If denied, you have 180 days to appeal internally, then external review through Florida
6 min read

How to Get Pomalyst (Pomalidomide) Covered by Aetna (CVS Health) in Texas: Complete Prior Authorization and Appeals Guide

Answer Box: Getting Pomalyst (Pomalidomide) Covered by Aetna (CVS Health) in Texas Aetna (CVS Health) requires prior authorization for Pomalyst (pomalidomide) with documented failure of both lenalidomide and a proteasome inhibitor, plus mandatory PS-Pomalidomide REMS enrollment. To get approval in Texas: (1) Complete REMS certification through the BMS portal within
6 min read

Lowering Out-of-Pocket Costs for Enhertu with UnitedHealthcare in North Carolina: Copay Cards, Tiering Appeals, and Financial Assistance

Answer Box: Enhertu (fam-trastuzumab deruxtecan-nxki) costs $150,000+ annually but UnitedHealthcare commercial patients can reduce out-of-pocket to $0 drug cost plus $100/infusion using the ENHERTU4U copay program. Submit prior authorization via UnitedHealthcare Provider Portal with HER2-positive pathology results and prior therapy documentation. If denied, appeal internally within 180 days,
6 min read